A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001]

Exclusion Criteria

• •Patients with serum creatinine concentration of 2.5 mg/dL or higher at the screening examination
• •Patients with any of the following complications
• •* Uncontrolled hypertension
• •* Serious cardiovascular disease (eg. heart failure) or hepatic disease (eg. cirrhosis)"
• •Patients with any of the following complications or history thereof
• •* Clinically significant drug allergies (anaphylaxis) or hypersensitivity (especially, hypersensitivity to benzazepine derivatives or suspected hypersensitivity thereto)
• •* Inability to personally give consent due to a mental disease "
• •Patients with SBP (in sitting position) \<90 mm Hg (at screening examination)
• •Patients with history of massive bleeding or bleeding tendency
• •Patients with a history of drug or alcohol abuse within 6 months prior to the screening examination
• •Pregnant women, lactating women, or women who may become or plan to become pregnant
• •Patients who received any investigational drug other than OPC-41061 within 30 days prior to commencement of administration of OPC-41061
• •Any patient who, in the opinion of the principle investigator or attending investigators, should not participate in the study